Back to search results

Understanding How We Talk About New Cancer Drugs

This study is looking at how different ways of talking about new cancer drugs affect people's understanding and decisions. Researchers want to see if brief statements about uncertainties with a drug's evidence, like whether Zenova has been compared to other treatments or how long patients were followed, change how people think about it. You would be given information about a hypothetical new drug called Zenova for non-small cell lung cancer. The study aims to enroll 3000 adults who are at least 18 years old, fluent in English, and live in the United States. Success in this study means seeing how these statements change people's decisions and understanding, measured through a 15-minute survey.

Study design
This is a randomized survey study involving 3000 adults. Participants will be given information about a hypothetical drug and then randomly assigned to read one of five statements about uncertainties with its evidence.
What's involved
You would participate in a 15-minute survey. This involves answering questions before and after reading a statement about a hypothetical drug.
Compensation
Not stated in the trial record.
Follow-up
Your understanding and decisions will be measured immediately after the intervention, during the 15-minute survey.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06997185

Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs

Recruiting
NAAges 18+Interventional
London School of Economics and Political Science
~3,000 participants
Updated 2025-05-30 on ClinicalTrials.gov
What's tested:Statement communicating uncertainty with a single arm trialStatement communicating uncertainty with limited study durationStatement communicating uncertainty with a limited study populationStatement communicating uncertainty with an unvalidated surrogate endpointStatement communicating uncertainty with treatment effect size

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in decisions
Measured over 15-minute survey. Change in decisions is assessed by participants answers to the question pre- and post-intervention.
+1 more outcome measured

Conditions

Cancer

Explore related trials

Malignant Neoplasm

Where it's being run

1 sites across 1 states
Massachusetts1

Who to contact

Avi Cherla
[email protected]
16172011718
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults 18 years of age and older
Adults fluent in English
Adults residing in the United States

What this trial measures

  • Change in decisions15-minute survey. Change in decisions is assessed by participants answers to the question pre- and post-intervention.

    "Imagine you were Alex and diagnosed with non-small cell lung cancer. How likely are you to take the new drug, Zenova?" 4-point Likert scale for decision: very likely; somewhat likely; somewhat unlikely; very unlikely.

  • Understanding15-minute survey. Assessed post-intervention.

    Please answer rate your agreement with the following statements. Zenova works better than other treatments for non-small cell lung cancer Zenova's longer-term benefits and harms are well known Zenova has been studied in patients that are similar to Alex (race and ethnicity) Zenova improves how patients feel or how long they live Zenova has a very large benefit for patients with non-small cell lung cancer 5-point Likert scale for understanding: strongly disagree; somewhat disagree; neither disagree or agree; somewhat agree; strongly agree.